Thermo Fisher Scientific Human TDP-43 Synthetic Peptide

Applications

Tested Dilution

Publications

Control (Ctrl)

Assay-dependent

-

Blocking Assay (BLOCK)

Assay-dependent

-

Product Specifications

Species Reactivity

Human

Class

Synthetic

Type

Peptide

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

200 µg/mL

Purification

purified

Storage buffer

PBS, pH 7.2, with 0.1% BSA

Contains

0.02% sodium azide

Storage conditions

-20°C

Product Specific Information

This peptide corresponds to 15 amino acids near the carboxy terminus of human TDP43.

PEP-0525 can be used as a blocking peptide with polyclonal antibody PA5-20408.

Target Information

TDP43 was first identified as a novel cellular protein that binds to HIV-1 virus TAR DNA sequence motifs and acts a transcriptional repressor to the HIV-1 LTR. Later experiments revealed that TDP43 also regulates the splicing of exon 9 of the cystic fibrosis transmembrane conductance regular (CFTR), most likely through the association with the UG repeats at the 3`e; splice site. A hyperphosphorylated, ubiquitinated, and cleaved form of TDP43 known as pathologic TDP43 is the major disease protein in ubiquitin-positive, tau-, and alpha-synuclein-negative frontotemporal dementia (FLTD-U). TDP43 is not related to TRBP1, and RNA binding protein that binds HIV-1 TAR RNA sequences.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.